Last updated: August 28, 2026
Etomidate is an off-patent intravenous anesthetic used mainly for induction of general anesthesia and rapid-sequence intubation. Its commercial market is mature, genericized, and price-sensitive. Revenue growth is driven by hospital procedure volumes, emergency medicine use, supply reliability, and geographic expansion rather than proprietary pricing power. No major branded patent or biologic exclusivity barrier currently protects etomidate injection in the United States.
What is etomidate used for?
Etomidate is a short-acting intravenous hypnotic that produces anesthesia without meaningful analgesia. U.S. labeling identifies it for the induction of general anesthesia and for short-duration procedures when administered by trained personnel with airway-management capabilities (FDA, 2023).
The drug is commonly used in:
- Operating-room anesthesia induction
- Emergency-department rapid-sequence intubation
- Prehospital airway management
- Intensive-care-unit procedures
- Cardioversion and other short procedures
- Veterinary anesthesia
Its principal commercial formulation is etomidate injection at 2 mg/mL. Common presentations include 10-mL vials containing 20 mg and 20-mL vials containing 40 mg, although available package sizes vary by manufacturer and market.
Etomidate has a rapid onset, generally within one minute after intravenous administration, and a short duration of hypnosis. It is often selected when clinicians want to limit blood-pressure depression during induction. The drug can cause myoclonus, nausea, vomiting, injection-site pain, and transient adrenal suppression. It does not provide analgesia and is not a substitute for opioid or other pain-control therapy.
How large is the etomidate market?
Public market estimates for etomidate are fragmented and vary substantially by geographic scope, product definition, and inclusion of hospital-use products. Manufacturers rarely report etomidate revenue separately because it is generally included within broader injectable anesthetic or hospital pharmaceuticals segments.
The commercial market is best characterized as a small, mature generic injectable market rather than a high-growth specialty pharmaceutical segment.
| Market factor |
Effect on etomidate demand |
| Surgical volume |
Supports baseline operating-room demand |
| Emergency intubation |
Creates recurring demand outside the operating room |
| Generic competition |
Restricts price increases and gross margins |
| Hospital purchasing groups |
Concentrate purchasing power and pressure pricing |
| Drug shortages |
Can temporarily increase supplier pricing and reorder volumes |
| Adrenal-suppression concerns |
Limits use in some critical-care and sepsis protocols |
| Propofol and ketamine availability |
Creates substitution risk |
| Veterinary use |
Adds a smaller but distinct demand channel |
| International hospital expansion |
Supports long-term unit growth in emerging markets |
The financial trajectory is therefore volume-led. Unit demand can rise with procedure and intubation volumes, but revenue growth is usually constrained by generic price competition. A manufacturer with reliable supply, broad distribution, and low-cost sterile manufacturing can gain share even without differentiated clinical claims.
What companies manufacture or distribute etomidate?
Etomidate is supplied by generic injectable-drug companies and specialty hospital-product distributors. Historical and current U.S. labels have included products associated with Hospira, a Pfizer company, and other generic manufacturers and authorized distributors. Product availability can change as manufacturers enter or leave the market.
The principal competitive attributes are:
- FDA-approved injectable presentation
- Manufacturing reliability and sterile-fill capacity
- Vial sizes and hospital-compatible packaging
- Contracting access through group purchasing organizations
- Ability to maintain supply during shortages
- Distribution coverage across hospitals, ambulances, and emergency departments
Unlike branded small-molecule products, etomidate suppliers generally compete on price, availability, quality history, and contracting terms. A manufacturer with a single facility or limited supplier base faces greater operational exposure than a supplier with redundant sterile-manufacturing capacity.
What patents protect etomidate?
The original proprietary protection for etomidate expired decades ago. The active ingredient is an established small molecule, and etomidate injection is marketed as a generic product.
Patent estate and exclusivity
| Protection category |
Current commercial relevance |
| Original compound patent |
Expired |
| Original formulation protection |
Expired or commercially irrelevant |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
No known current market significance |
| Orphan-drug exclusivity |
Not applicable to standard etomidate injection |
| Biosimilar exclusivity |
Not applicable |
| Generic injectable patents |
No widely recognized blocking U.S. estate |
| Trade-secret manufacturing know-how |
Potentially relevant at the supplier level |
The principal intellectual-property barriers are manufacturing know-how, sterile-processing controls, supplier qualification, regulatory compliance, and capacity. These barriers can affect market entry even when patent protection is absent.
Because etomidate products are generally approved through abbreviated or generic pathways, the commercial analysis should focus on active FDA approvals, manufacturing status, facility inspections, supply history, and contracting position rather than on a branded patent cliff.
What is the Orange Book status of etomidate?
Etomidate injection products are generic prescription drugs and do not have the type of innovative-product exclusivity associated with a currently protected branded medicine. The FDA Orange Book identifies approved drug products and relevant patent or exclusivity information, but the practical commercial position of etomidate is that of an established generic injectable (FDA, 2024a).
An Orange Book review should distinguish:
- The reference-listed drug
- Approved abbreviated new drug applications
- Current marketing status
- Any listed patents
- Therapeutic-equivalence evaluations
- Products that have been discontinued but remain listed
A listed product is not necessarily commercially active. Generic injectable markets can have a smaller number of active suppliers than the number of historical FDA listings suggests.
When does etomidate lose exclusivity?
Etomidate lost meaningful market exclusivity before the modern generic market was established. It is not approaching a future U.S. patent cliff. The relevant commercial question is supply concentration, not loss of exclusivity.
The original product, marketed historically as Amidate, was introduced decades ago. Current products are supplied through generic channels, with approval and labeling governed by the FDA. Any manufacturer entering the U.S. market would normally pursue an ANDA or another applicable FDA pathway rather than wait for an upcoming patent expiration.
Are there Paragraph IV challenges to etomidate?
Paragraph IV litigation is not a central current risk for etomidate. Paragraph IV certifications are most commercially important when a generic applicant challenges active patents listed for a branded reference product. Etomidate is already a mature generic product with no widely recognized blocking patent estate comparable to protected products such as branded GLP-1 agonists, oncology therapies, or biologics.
Potential disputes are more likely to involve:
- ANDA approval or deficiency issues
- Product-quality allegations
- Sterile-manufacturing compliance
- Supply contracts
- Trademark or labeling matters
- Patent claims directed to a new formulation or delivery system
A new proprietary etomidate formulation could create a different litigation profile, particularly if it claimed reduced injection pain, lower myoclonus, modified adrenal effects, or a novel delivery system. Those claims would require separate patent and regulatory analysis.
What formulations are protected by etomidate patents?
The commercially established formulation is an injectable solution containing etomidate at approximately 2 mg/mL. Standard products use a solvent system designed for intravenous administration. Formulation-level differentiation has limited commercial penetration.
Potential formulation innovation areas include:
- Reduced injection pain
- Lipid-based emulsions
- Alternative solvents
- Premixed syringes
- Ready-to-administer emergency products
- Improved stability or storage conditions
- Pediatric or prehospital packaging
- Combination products for anesthesia protocols
These concepts could support patent filings, but a patent application would not itself create commercial value. The formulation would also need FDA approval, clinical support, manufacturing validation, and hospital adoption. A reformulated product would face competition from low-cost generic etomidate and established alternatives such as propofol and ketamine.
How does etomidate compare with propofol and ketamine?
Etomidate competes primarily with propofol and ketamine in induction and emergency airway management. Thiopental and midazolam remain relevant in selected settings but have smaller or more specialized roles in many U.S. institutions.
| Attribute |
Etomidate |
Propofol |
Ketamine |
| Primary role |
Induction and emergency intubation |
Induction and procedural sedation |
Induction, sedation, analgesia |
| Analgesia |
No |
No |
Yes |
| Hemodynamic profile |
Often selected for relative stability |
More blood-pressure depression |
Can increase sympathetic tone |
| Adrenal effects |
Transient adrenal suppression |
No comparable effect |
No comparable etomidate effect |
| Common adverse effects |
Myoclonus, nausea, injection pain |
Hypotension, respiratory depression |
Emergence reactions, hypersalivation |
| Generic status |
Generic |
Generic |
Generic |
| Main commercial risk |
Substitution and supply pressure |
Broad substitute and strong hospital use |
Expanding emergency and procedural use |
Clinical selection depends on patient condition, indication, institutional protocol, and clinician preference. Concerns about adrenal suppression have limited routine or repeated use in some critically ill patients. The FDA label warns that etomidate does not provide analgesia and identifies adrenal cortical suppression as a pharmacologic effect relevant to clinical use (FDA, 2023).
What FDA regulatory issues affect etomidate?
Etomidate is regulated as a prescription injectable drug. Its commercial risks are concentrated in sterile manufacturing and product quality.
Key FDA-regulated issues include:
- Current good manufacturing practice compliance
- Sterility assurance
- Visible and subvisible particulate control
- Container-closure integrity
- Label accuracy
- Injectable-product stability
- Facility inspection outcomes
- Product discontinuation reporting
- Drug-shortage notifications
Injectable products have higher operational sensitivity than many oral generics because manufacturing failures can remove a product from hospital formularies quickly. A single facility interruption can create a temporary market imbalance even when several historical suppliers exist.
The FDA Drug Shortages database is the relevant source for assessing current availability, shortage status, and manufacturer-specific supply conditions (FDA, 2024b).
What patent litigation affects etomidate?
No major, widely reported U.S. patent litigation currently defines the etomidate market. The absence of a significant active patent dispute reduces legal barriers to generic supply but does not eliminate regulatory or commercial litigation risk.
Potential litigation exposure includes:
- Product-liability claims involving adverse effects
- Failure-to-warn allegations
- Manufacturing-defect claims
- Hospital procurement disputes
- Distributor contract disputes
- Competition claims arising from supply interruptions
The highest-value legal diligence is usually a review of current FDA approvals, warning letters, recalls, inspection history, product liability filings, and manufacturer-specific supply performance.
What generic entry risks exist for etomidate?
Generic entry risk is structurally high because the product is old, clinically familiar, and technically straightforward relative to complex biologics or sustained-release products. The principal limitation is not patent access but sterile injectable economics.
A new entrant must overcome:
- Validation costs for sterile manufacturing
- FDA review and inspection requirements
- Hospital contracting barriers
- Low expected unit prices
- Established supplier relationships
- Inventory and shortage-management requirements
- Commercial scale needed to offset limited per-unit margins
Entry can still be attractive when the market has few active suppliers or experiences recurring shortages. A reliable entrant may obtain meaningful share without offering a novel clinical product.
What is the financial trajectory for etomidate?
Etomidate revenue is likely to remain stable to modestly growing in units, with limited pricing expansion. The strongest long-term drivers are:
- Growth in surgical procedures
- Higher emergency-department utilization
- Expansion of critical-care infrastructure
- Increased prehospital airway-management capability
- Demand from veterinary markets
- Supplier exits or shortage events
The main financial constraints are generic price erosion, substitution by propofol or ketamine, and low product differentiation. Gross-margin performance depends heavily on manufacturing cost, facility utilization, procurement contracts, and shortage conditions.
Revenue exposure by business model
| Business model |
Revenue outlook |
Main risk |
| Low-cost generic injectable |
Stable volume, low margin |
Price competition |
| Specialty hospital supplier |
Potential share gains |
Contract concentration |
| Shortage-resilient manufacturer |
Temporary pricing leverage |
Supply normalization |
| Novel formulation developer |
Higher potential margin |
Clinical and regulatory cost |
| Distributor |
Low differentiation |
Manufacturer dependence |
| Veterinary-focused supplier |
Niche growth |
Smaller addressable market |
No major branded-company revenue stream appears dependent on etomidate alone. For diversified manufacturers, the drug is more likely to contribute incremental hospital-product revenue than to determine corporate financial performance.
What is the geographic coverage of etomidate?
Etomidate is marketed internationally as an injectable anesthetic, but product names, regulatory status, presentations, and approved indications vary by jurisdiction. The strongest commercial demand is concentrated in markets with established surgical infrastructure, emergency medical systems, and hospital procurement networks.
Geographic expansion depends on:
- Local registration requirements
- Import and serialization rules
- Sterile-product manufacturing capacity
- Public-hospital tenders
- Pricing controls
- Emergency-medicine adoption
- Availability of competing induction agents
U.S. and European markets are mature and price-sensitive. Emerging markets may offer higher unit growth but generally carry lower prices, tender exposure, and distribution complexity.
Key Takeaways
- Etomidate is a mature, off-patent generic injectable anesthetic.
- No major future patent cliff or active branded exclusivity event drives the market.
- The commercial market is shaped by hospital procedure volumes, emergency intubation, supply reliability, and generic pricing.
- The main competitive products are propofol and ketamine.
- Adrenal suppression and lack of analgesia limit use in selected clinical settings.
- Sterile manufacturing, FDA compliance, and supply continuity are more important than patent barriers.
- A new entrant could gain share if it offers dependable supply, competitive pricing, or a differentiated formulation.
- Financial growth is likely to be modest and volume-driven, with limited pricing power.
- Public company filings generally do not isolate etomidate revenue, making product-level revenue attribution difficult.
- The principal diligence priorities are active FDA approvals, current manufacturers, shortage status, recalls, inspection history, and hospital-contracting exposure.
FAQs
Is etomidate still under patent protection?
No meaningful original-product patent protection remains commercially relevant. Etomidate is marketed primarily through generic injectable products.
Is etomidate a controlled substance?
Etomidate is not generally treated as a federally scheduled controlled substance in the United States. It remains a prescription anesthetic subject to FDA regulation and institutional controls.
Can a generic company launch etomidate without a Paragraph IV challenge?
Yes. A generic applicant may pursue an applicable FDA approval pathway without challenging an active listed patent if no blocking patent claims the product or its approved use.
Does etomidate have biosimilar competition?
No. Etomidate is a chemically synthesized small molecule, not a biologic. The relevant competitors are generic injectable products, not biosimilars.
What could create a premium etomidate product?
A premium product would need a clinically relevant distinction, such as reduced injection pain, improved stability, prefilled emergency packaging, simpler administration, or a formulation that addresses a recognized limitation of standard etomidate.
References
-
U.S. Food and Drug Administration. (2023). Etomidate injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024b). Drug shortages database. FDA.
-
DailyMed. (2024). Etomidate injection, solution prescribing information. National Library of Medicine.
-
Pfizer Inc. (2023). Hospira injectable pharmaceutical products and prescribing information. Pfizer.
